GOT1 and neoplasm: Recent studies have shown that SIRT5 depletion enhances glutamine and glutathione metabolism and promotes tumorigenesis through acetylation-mediated glutamate oxaloacetate transaminase 1 (GOT1) activation, while the SIRT5-selective activator MC3138 inhibits the proliferation of tumor cells [47].